Inhibrx Biosciences Set to Showcase Innovative Research at ESMO Congress Inhibrx Biosciences is preparing to present groundbreaking findings on a novel drug combination for Ewing Sarcoma at the ESMO conference in March 2026.

Inhibrx Biosciences Set to Showcase Innovative Research at ESMO Congress #USA #San_Diego #Inhibrx #ESMO_Congress #Ewing_Sarcoma

Transcriptional regulation of KCNA2 coding Kv1.2 by EWS::FLI1: involvement in controlling the YAP/Hippo signalling pathway and cell proliferation - Cell Communication and Signaling Background Ewing sarcoma (ES), the second main pediatric bone sarcoma, is characterised by a chromosomal translocation leading to the formation of fusion proteins like EWS::FLI1. While several studies...

Very pleased to share our last collaborative publication with Child team #CRCI2NA @inserm.fr @insermgrandouest.bsky.social #cancéropole_Grand_Ouest #Ewing_sarcoma #KCNA2 #Kv1.2 #EWS::FLI1 #YAP/Hippo

biosignaling.biomedcentral.com/articles/10....